A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.
Stopped The study was discontinued by the Sponsor because it did not achieve the primary objective.
Conditions
Interventions
- DRUG: UNR844
- DRUG: Placebo
Sponsor
Novartis Pharmaceuticals